What records are connected here?
- Evidence lanes
- 1
- Source years
- 3
- Drugs@FDA applications
- 0
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
In clinical trials3,4,5Evidence: Smaller human trialsMetabolic and weight
Avexitide is a synthetic peptide, the 9-39 fragment of exendin, that blocks the GLP-1 receptor, according to trial investigators.3,4 It is being developed for dangerously low blood sugar after meals in people who have had bariatric surgery. In a small placebo-controlled crossover trial of 18 women, it raised the lowest blood sugar after a test meal by about a fifth to a quarter.4 No FDA approval is reported in the sources reviewed here, and avexitide is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.3,8
| What it is | A synthetic 31-amino-acid peptide amide, exendin (9-39), recorded as avexitide acetate in FDA’s substance registry; trial authors describe it as a GLP-1 receptor antagonist.3,4 |
|---|---|
| FDA status | Not FDA-approved. None of the sources reviewed here reports an approval of avexitide.3,4 |
| Human evidence | Small trials in post-bariatric hypoglycemia: a placebo-controlled crossover trial in 18 women and a 2026 Phase 2b study in 16 completers without a placebo group.4,5 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
Avexitide is a synthetic peptide matching amino acids 9 to 39 of exendin-3, a lizard peptide, and ending in an amide. FDA’s substance registry records it as avexitide acetate, with exendin (9-39) amide acetate among its names.3
The PREVENT investigators describe avexitide as a GLP-1 receptor antagonist. After some stomach surgeries, the gut releases excess GLP-1 after meals, which can drive insulin too high and blood sugar too low; blocking the receptor is meant to blunt that.4,5
In PREVENT, 18 women with post-bariatric hypoglycemia received placebo for 14 days and then avexitide for two further periods in randomized sequence. Compared with placebo, avexitide raised the lowest blood sugar during a test meal by 21% and 26% and lowered peak insulin.4
In a 2026 Phase 2b study of 16 completers after bariatric and other upper stomach surgeries, avexitide reduced the rate of significant low blood sugar events by about half compared with a run-in period, with no serious adverse events reported. The study had no placebo group.5
ClinicalTrials.gov lists a Phase 3 trial of avexitide in post-bariatric hypoglycemia (NCT06747468) as active, not recruiting, in its August 24, 2026 record.1
Evidence-strength label: Smaller controlled human trials. How this label is assigned
None of the sources reviewed here reports an approval of avexitide by FDA. The 2021 PREVENT report states that there was no approved therapy for post-bariatric hypoglycemia.3,4
Avexitide remains in clinical trials: its Phase 3 registration (NCT06747468) is listed as active, not recruiting, in its August 24, 2026 record.1
FDA’s compounding safety-risk page, current as of April 22, 2026, does not list avexitide.6
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Avexitide is not among them.7,8
Whether its benefits hold in larger and longer trials: the published studies enrolled fewer than 20 people each and lasted weeks.4,5
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Avexitide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Avexitide are a bounded selection, not every registration or paper about Avexitide. For the years before Avexitide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Avexitide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Avexitide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
In clinical trials; not FDA-approved. Small trials, including a placebo-controlled crossover trial in 18 women, found higher blood sugar lows and fewer hypoglycemia events. Avexitide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
In clinical trials; not FDA-approved. Small trials, including a placebo-controlled crossover trial in 18 women, found higher blood sugar lows and fewer hypoglycemia events. Avexitide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Clinical trials · source date August 24, 2026
ClinicalTrials.gov record NCT06747468↗Added to PeptideScanner November 16, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT06747468↗Source date August 24, 2026Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT04652479↗Source date June 9, 2023Clinical trials · added November 16, 2026
ClinicalTrials.gov record NCT03373435↗Source date July 18, 2022PeptideScanner currently has no selected PubMed literature metadata records, regulatory records, and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
3 of 3 selected trial records include at least one phase value; 3 of 3 include a status value in the retained structured contract.
0 of 0 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT03373435 at 2026-11-16T01:46:44.871Z. Its registry update date was 2022-07-18, and PeptideScanner's reviewed identity mapping was avexitide.
PeptideScanner retained ClinicalTrials.gov record NCT04652479 at 2026-11-16T01:46:44.871Z. Its registry update date was 2023-06-09, and PeptideScanner's reviewed identity mapping was avexitide.
PeptideScanner retained ClinicalTrials.gov record NCT06747468 at 2026-11-16T01:46:44.871Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was avexitide.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Selected records span July 18, 2022 to August 24, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06747468 at 2026-11-16T01:46:44.871Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was avexitide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04652479 at 2026-11-16T01:46:44.871Z. Its registry update date was 2023-06-09, and PeptideScanner's reviewed identity mapping was avexitide.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03373435 at 2026-11-16T01:46:44.871Z. Its registry update date was 2022-07-18, and PeptideScanner's reviewed identity mapping was avexitide.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
ClinicalTrials.gov · Official source · Source checked November 16, 2026
ClinicalTrials.gov · Official source · Source checked November 16, 2026
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
The Journal of Clinical Endocrinology & Metabolism · Official source · Source checked November 15, 2026
Metabolism: Clinical and Experimental · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026